Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2012

01.07.2012 | Epidemiology

Long-term survival of older breast cancer patients: population-based estimates over three decades

verfasst von: Bindu Kanapuru, William B. Ershler, Charles Hesdorffer, Ahmedin Jemal, Jerome W. Yates

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Significant progress has been made in the treatment of breast cancer. However, treatment effect on survival in older patients, particularly the “oldest old” (85+ years), with breast cancer is not clear. Data from the Surveillance, Epidemiology, and End Results databases were used to determine relative survival of older patients with breast cancer for up to 9 years following diagnosis. We compared trends in survival and stage distribution in the years 1977–1986, 1987–1996, and 1997–2006 in patients from 65 to 74, 75 to 84, and 85+ years of age. Between 1977–1986 and 1997–2006, 1 year survival increased from 94.9 to 97.9 %, 93.6 to 96.7 %, and 88.5 to 93.5 % in the 65–74, 75–84, and 85+ age groups, respectively. Survival gains increased with each year in all three age groups with the largest improvement seen at 9 years of follow-up. Although the “oldest old” had the lowest survival rates, improvement in survival was greatest in this age group with greater than 20 % increase in survival at 9 years. There was an increased diagnosis of localized breast cancer and decrease in regional disease in all age groups over the three decades. In conclusion, relative survival for older patients has increased considerably in the interval between 1977 and 2006, with the largest improvement seen in those 85 years and older. These results likely indicate that the benefit from advances in therapy and supportive care also extends to older patients with breast cancer, including the ‘oldest old’, but the impact of early diagnosis on survival requires further clarification.
Literatur
1.
Zurück zum Zitat Rosso S, Gondos A, Zanetti R et al (2010) Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer 46:3351–3357PubMedCrossRef Rosso S, Gondos A, Zanetti R et al (2010) Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer 46:3351–3357PubMedCrossRef
2.
Zurück zum Zitat Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156PubMedCrossRef Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M156PubMedCrossRef
3.
Zurück zum Zitat Yancik R, Wesley MN, Ries LA et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885–892PubMedCrossRef Yancik R, Wesley MN, Ries LA et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885–892PubMedCrossRef
4.
Zurück zum Zitat Smith BD, Smith GL, Hurria A et al (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27:2758–2765PubMedCrossRef Smith BD, Smith GL, Hurria A et al (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27:2758–2765PubMedCrossRef
5.
Zurück zum Zitat Cherubini A, Del Signore S, Ouslander J et al (2010) Fighting against age discrimination in clinical trials. J Am Geriatr Soc 58:1791–1796PubMedCrossRef Cherubini A, Del Signore S, Ouslander J et al (2010) Fighting against age discrimination in clinical trials. J Am Geriatr Soc 58:1791–1796PubMedCrossRef
6.
Zurück zum Zitat Horner MJ, Ries LSG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds) (2009) SEER cancer statistics review, 1975–2006. National Cancer Institute, Bethesda. http://seer.cancer.gov/csr/1975_2006/. Based on November 2008 SEER data submission, posted to the SEER web site Horner MJ, Ries LSG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds) (2009) SEER cancer statistics review, 1975–2006. National Cancer Institute, Bethesda. http://​seer.​cancer.​gov/​csr/​1975_​2006/​. Based on November 2008 SEER data submission, posted to the SEER web site
7.
Zurück zum Zitat Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792PubMedCrossRef Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792PubMedCrossRef
8.
Zurück zum Zitat Mariotto A, Feuer EJ, Harlan LC et al (2002) Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst 94:1626–1634PubMedCrossRef Mariotto A, Feuer EJ, Harlan LC et al (2002) Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst 94:1626–1634PubMedCrossRef
9.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717CrossRef
10.
Zurück zum Zitat BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766–776 BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766–776
11.
Zurück zum Zitat Giordano SH, Duan Z, Kuo YF et al (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24:2750–2756PubMedCrossRef Giordano SH, Duan Z, Kuo YF et al (2006) Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 24:2750–2756PubMedCrossRef
12.
Zurück zum Zitat Muss HB, Berry DA, Cirrincione CT et al (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055–2065PubMedCrossRef Muss HB, Berry DA, Cirrincione CT et al (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055–2065PubMedCrossRef
13.
Zurück zum Zitat Randolph WM, Goodwin JS, Mahnken JD et al (2002) Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis. Ann Intern Med 137:783–790PubMed Randolph WM, Goodwin JS, Mahnken JD et al (2002) Regular mammography use is associated with elimination of age-related disparities in size and stage of breast cancer at diagnosis. Ann Intern Med 137:783–790PubMed
14.
Zurück zum Zitat Badgwell BD, Giordano SH, Duan ZZ et al (2008) Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol 26:2482–2488PubMedCrossRef Badgwell BD, Giordano SH, Duan ZZ et al (2008) Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol 26:2482–2488PubMedCrossRef
15.
Zurück zum Zitat Schonberg MA, Marcantonio ER, Li D et al (2010) Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol 28:2038–2045PubMedCrossRef Schonberg MA, Marcantonio ER, Li D et al (2010) Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol 28:2038–2045PubMedCrossRef
16.
Zurück zum Zitat Vercelli M, Capocaccia R, Quaglia A et al (2000) Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE Working Group. Crit Rev Oncol Hematol 35:161–179PubMedCrossRef Vercelli M, Capocaccia R, Quaglia A et al (2000) Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE Working Group. Crit Rev Oncol Hematol 35:161–179PubMedCrossRef
17.
Zurück zum Zitat Bouchardy C, Rapiti E, Fioretta G et al (2003) Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21:3580–3587PubMedCrossRef Bouchardy C, Rapiti E, Fioretta G et al (2003) Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21:3580–3587PubMedCrossRef
Metadaten
Titel
Long-term survival of older breast cancer patients: population-based estimates over three decades
verfasst von
Bindu Kanapuru
William B. Ershler
Charles Hesdorffer
Ahmedin Jemal
Jerome W. Yates
Publikationsdatum
01.07.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2115-4

Weitere Artikel der Ausgabe 2/2012

Breast Cancer Research and Treatment 2/2012 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.